Cost Effectiveness of Pharmacotherapies for Attention-Deficit Hyperactivity Disorder
暂无分享,去创建一个
V. Sikirica | R. Ben-Hamadi | Jipan Xie | P. Hodgkins | E. Wu | M. Erder | M. Erder | E. Du | J. Setyawan | Sherry Yan | Eric Q. Wu | Ella X. Du | Sherry Y. Yan
[1] V. Sikirica,et al. Cost Effectiveness of Guanfacine Extended Release as an Adjunctive Therapy to a Stimulant Compared with Stimulant Monotherapy for the Treatment of Attention-Deficit Hyperactivity Disorder in Children and Adolescents , 2012, PharmacoEconomics.
[2] V. Sikirica,et al. PIH23 Cost-Effectiveness of Guanfacine Extended Release as an Adjunctive Therapy to a Psychostimulant Compared to Psychostimulant Monotherapy for the Treatment of Attention Deficit/Hyperactivity Disorder in Children and Adolescents , 2011 .
[3] D. Huse,et al. Adult ADHD: prevalence of diagnosis in a US population with employer health insurance , 2011, Current medical research and opinion.
[4] J. Thome,et al. Pharmacological treatment of adult ADHD in Europe , 2011, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.
[5] S. Dewilde,et al. Methylphenidate delivery mechanisms for the treatment of children with attention deficit hyperactivity disorder: Heterogeneity in parent preferences , 2011, International Journal of Technology Assessment in Health Care.
[6] V. Sikirica,et al. PMH37 THE COST-EFFECTIVENESS OF GUANFACINE EXTENDED RELEASE (GXR) VERSUS ATOMOXETINE (ATX) FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD) IN CHILDREN AND ADOLESCENTS , 2011 .
[7] D. Huse,et al. Cost of illness and comorbidities in adults diagnosed with attention-deficit/hyperactivity disorder: a retrospective analysis. , 2011, The primary care companion for CNS disorders.
[8] N. Halfon,et al. Patterns of Comorbidity, Functioning, and Service Use for US Children With ADHD, 2007 , 2011, Pediatrics.
[9] K. Föhr,et al. Dose-dependent modulation of apoptotic processes by fluoxetine in maturing neuronal cells: an in vitro study , 2011, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.
[10] S. Faraone,et al. Predictors of persistent ADHD: an 11-year follow-up study. , 2011, Journal of psychiatric research.
[11] D. Coghill. The Impact of Medications on Quality of Life in Attention-Deficit Hyperactivity Disorder , 2010, CNS drugs.
[12] M. Brams,et al. Duration of effect of oral long-acting stimulant medications for ADHD throughout the day , 2010, Current medical research and opinion.
[13] L. Davis,et al. Atomoxetine and neuropsychological function in children with attention-deficit/hyperactivity disorder: results of a pilot study. , 2009, Journal of child and adolescent psychopharmacology.
[14] Jason M. Fletcher,et al. Long-Term Consequences of Childhood ADHD on Criminal Activities , 2009, The journal of mental health policy and economics.
[15] J. Ioannidis,et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. , 2009, Journal of clinical epidemiology.
[16] J. Buitelaar,et al. The quality of life of children with attention deficit/hyperactivity disorder: a systematic review , 2009, European Child & Adolescent Psychiatry.
[17] J. Ioannidis,et al. The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration , 2009, Annals of Internal Medicine [serial online].
[18] J. McGough,et al. Long-term safety and efficacy of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. , 2009, Journal of child and adolescent psychopharmacology.
[19] Brent D. Fulton,et al. Positive Association Between Attention-Deficit/ Hyperactivity Disorder Medication Use and Academic Achievement During Elementary School , 2009, Pediatrics.
[20] T. Dilla,et al. A modelled economic evaluation comparing atomoxetine with methylphenidate in the treatment of children with attention-deficit/hyperactivity disorder in Spain , 2009, BMC psychiatry.
[21] S. Bálint,et al. Prevalence and correlates of adult attention-deficit hyperactivity disorder: meta-analysis , 2009, British Journal of Psychiatry.
[22] L. Habel,et al. Mothers of Children Diagnosed With Attention-Deficit/Hyperactivity Disorder: Health Conditions and Medical Care Utilization in Periods Before and After Birth of the Child , 2009, Medical care.
[23] J. Biederman,et al. Long-Term, Open-Label Extension Study of Guanfacine Extended Release in Children and Adolescents with ADHD , 2008, CNS Spectrums.
[24] J Ormel,et al. The prevalence and effects of adult attention-deficit/hyperactivity disorder (ADHD) on the performance of workers: results from the WHO World Mental Health Survey Initiative , 2008, Occupational and Environmental Medicine.
[25] M. Aristides,et al. A modeled economic evaluation comparing atomoxetine with stimulant therapy in the treatment of children with attention-deficit/hyperactivity disorder in the United Kingdom. , 2008, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[26] William E Pelham,et al. The economic impact of attention-deficit/hyperactivity disorder in children and adolescents. , 2007, Ambulatory pediatrics : the official journal of the Ambulatory Pediatric Association.
[27] B. Horta,et al. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. , 2007, The American journal of psychiatry.
[28] J. Buitelaar,et al. Societal costs and quality of life of children suffering from attention deficient hyperactivity disorder (ADHD) , 2007, European Child & Adolescent Psychiatry.
[29] L Eugene Arnold,et al. Treatment for ADHD: is more complex treatment cost-effective for more complex cases? , 2007, Health services research.
[30] D. Nutt,et al. Evidence-based guidelines for management of attention-deficit/hyperactivity disorder in adolescents in transition to adult services and in adults: recommendations from the British Association for Psychopharmacology , 2007, Journal of psychopharmacology.
[31] M. Drummond,et al. A systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents. , 2006, Health technology assessment.
[32] T. Wilens,et al. Long-term atomoxetine treatment in adolescents with attention-deficit/hyperactivity disorder. , 2006, The Journal of pediatrics.
[33] R. Kessler,et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. , 2006, The American journal of psychiatry.
[34] Joseph Biederman,et al. Young adult outcome of attention deficit hyperactivity disorder: a controlled 10-year follow-up study , 2006, Psychological Medicine.
[35] R. Weisler,et al. An Interim Analysis of the Quality of Life, Effectiveness, Safety, and Tolerability (QU.E.S.T.) Evaluation of Mixed Amphetamine Salts Extended Release in Adults With ADHD , 2005, CNS Spectrums.
[36] J. Swanson,et al. Cost-effectiveness of ADHD treatments: findings from the multimodal treatment study of children with ADHD. , 2005, The American journal of psychiatry.
[37] J. McGough,et al. Long-term tolerability and effectiveness of once-daily mixed amphetamine salts (Adderall XR) in children with ADHD. , 2005, Journal of the American Academy of Child and Adolescent Psychiatry.
[38] T. B. Üstün,et al. The Prevalence and Effects of Adult Attention Deficit/Hyperactivity Disorder on Work Performance in a Nationally Representative Sample of Workers , 2005, Journal of occupational and environmental medicine.
[39] R. Kessler,et al. Costs of attention deficit–hyperactivity disorder (ADHD) in the US: excess costs of persons with ADHD and their family members in 2000 , 2005, Current medical research and opinion.
[40] V. Harpin,et al. The effect of ADHD on the life of an individual, their family, and community from preschool to adult life , 2005, Archives of Disease in Childhood.
[41] L. Matza,et al. Health State Utilities for Childhood Attention-Deficit/Hyperactivity Disorder Based on Parent Preferences in the United Kingdom , 2005, Medical decision making : an international journal of the Society for Medical Decision Making.
[42] J. Hay,et al. Cost effectiveness of methylphenidate versus AMP/DEX mixed salts for the first-line treatment of ADHD , 2004, Expert review of pharmacoeconomics & outcomes research.
[43] A. Klassen,et al. Health-Related Quality of Life in Children and Adolescents Who Have a Diagnosis of Attention-Deficit/Hyperactivity Disorder , 2004, Pediatrics.
[44] T. Vos,et al. Cost-Effectiveness of Dexamphetamine and Methylphenidate for the Treatment of Childhood Attention Deficit Hyperactivity Disorder , 2004 .
[45] H. Birnbaum,et al. Attention-deficit/hyperactivity disorder: increased costs for patients and their families. , 2003, Journal of the American Academy of Child and Adolescent Psychiatry.
[46] L. Annemans,et al. A cost analysis of the management of attention-deficit/hyperactivity disorder (ADHD) in children in the UK , 2003 .
[47] J. Biederman,et al. Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder. , 2002, The Journal of clinical psychiatry.
[48] J. Swanson,et al. A double-blind, placebo-controlled study of modified-release methylphenidate in children with attention-deficit/hyperactivity disorder. , 2002, Pediatrics.
[49] T. Einarson,et al. Pharmacotherapies for attention-deficit/hyperactivity disorder: expected-cost analysis. , 2001, Clinical therapeutics.
[50] J. Wernicke,et al. Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. , 2001, Pediatrics.
[51] W. Pelham,et al. Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings. , 2001, Pediatrics.
[52] R. Milne,et al. Methylphenidate in children with hyperactivity: review and cost–utility analysis , 2001, Pharmacoepidemiology and drug safety.
[53] S. Zubrick,et al. The National Survey of Mental Health and Wellbeing: The Child and Adolescent Component , 2000, The Australian and New Zealand journal of psychiatry.
[54] T O Jefferson,et al. Guidelines for authors and peer reviewers of economic submissions to the BMJ , 1996, BMJ.
[55] S. Faraone,et al. Comorbidity of Diagnosis in Attention-Deficit Hyperactivity Disorder , 1992 .
[56] M. Fischer,et al. Assessment of Stimulant Response in ADHD Children Using a Refined Multimethod Clinical Protocol , 1991 .
[57] P. Szatmari,et al. Ontario Child Health Study: prevalence of attention deficit disorder with hyperactivity. , 1989, Journal of child psychology and psychiatry, and allied disciplines.
[58] J. Kevill,et al. ADHD: Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents , 2012 .
[59] R. Verma,et al. Management of attention-deficit hyperactivity disorder , 2011, Journal of Pediatric Neurosciences.
[60] Chika Akera,et al. ADHD: Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/ Hyperactivity Disorder in Children and Adolescents , 2011 .
[61] H. Tobi,et al. Long-Acting Methylphenidate-OROS in Youths with Attention-Deficit Hyperactivity Disorder Suboptimally Controlled with Immediate-Release Methylphenidate , 2008, CNS drugs.
[62] D. De Graeve,et al. Healthcare use, social burden and costs of children with and without ADHD in Flanders, Belgium. , 2006, Clinical drug investigation.
[63] J. Buitelaar,et al. Long-acting medications for the hyperkinetic disorders. A systematic review and European treatment guideline. , 2006, European child & adolescent psychiatry.
[64] J. Buitelaar,et al. European clinical guidelines for hyperkinetic disorder – first upgrade , 2004, European Child & Adolescent Psychiatry.
[65] P. Gillig,et al. Attention-Deficit/Hyperactivity Disorder in Adults , 2004 .
[66] K. Kavale,et al. Impact of ADHD on school systems. , 2002 .
[67] J. G. Gonzalez-Perez. Developing a scoring system to quality assess economic evaluations , 2002, The European Journal of Health Economics.
[68] F. Lynch,et al. Variations in pharmacotherapy for attention deficit hyperactivity disorder in managed care. , 2001, Journal of child and adolescent psychopharmacology.
[69] S. Paisley,et al. The clinical effectiveness and cost-effectiveness of methylphenidate for hyperactivity in childhood: assessment report. NICE Technology Appraisal (TA13) , 2000 .